Insights › Medicine & pharma › November 19, 2026
Medicine & pharma · Pipeline & development

Mile High Labs Files Type II Drug Master File with FDA for CBD Isolate

PR Newswire (Health) Published: Regulatory

Mile High Labs continues to build its pharmaceutical-channel capabilities with a Type II DMF for CBD Isolate LOVELAND, Colo., Nov. 19, 2026 /PRNewswire/ -- Mile High Labs, a global leader in hemp-derived cannabinoid ingredients, today announced that it has filed a Type II Drug Master File...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Medicine & pharma

See everything in Medicine & pharma →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.